- Home
- SRFM vs ENTX Comparison
SRFM vs ENTX Comparison
Compare SRFM & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | ENTX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.7M | 74.7M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SRFM | ENTX |
|---|---|---|
| Price | $2.39 | $1.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.81 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 5.4M | 290.0K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $108,158,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $1.77 | $1.45 |
| 52 Week High | $9.91 | $3.22 |
Technical Indicators
Market Signals| Indicator | SRFM | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 42.53 |
| Support Level | $2.38 | $1.55 |
| Resistance Level | $2.69 | $1.72 |
| Average True Range (ATR) | 0.30 | 0.15 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 1.33 | 47.22 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.